Navigation Links
Abbott Announces Labs Are Vital(TM) Facebook Scholarship Contest Winners
Date:4/24/2008

ime of recognition for the vital contributions of medical laboratory professionals and board-certified pathologists, than by introducing the winning students who represent the future of the profession."

"Without the lab, healthcare would come to an abrupt halt. There is no substitute for qualified laboratory professionals ensuring correct tests are ordered, performed accurately, and results utilized appropriately."

Edward L. Michael

Executive Vice President, Diagnostics, Abbott

"Abbott is committed to the laboratory profession, and, like our customers, we are concerned about its future. With the severe workforce shortage currently facing the lab, it's critical to inform the next generation about the exciting and life-saving work laboratory professionals perform each day that impacts patient care, safeguards public health, and protects our nation's blood supply.

Addressing Lab Workforce Shortage Through Recruitment

The average vacancy rate for staff medical technologists has increased 50 percent since 2003, according to the American Society for Clinical Pathology's (ASCP) 2005 wage and vacancy survey. Additionally, the U.S. Department of Labor estimates approximately 13,800 medical laboratory professionals will be needed every year through 2012 to fill vacant positions. Unfortunately, fewer than 5,000 professionals graduate from educational programs each year.

More than 70 percent of the objective information used to make diagnostic decisions -- which drive diagnosis and physician-prescribed treatment protocols -- is derived from the clinical lab.

Recruitment is one of many goals of the Labs Are Vital program. Others include improving the visibility of the clinical lab and demonstrating the value of the lab to the greater healthcare community. Abbott has been joined in this effort by many of the most influential professional organizations in the clinical lab arena, including: CLMA, American Society for Clinical
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
2. Smiths Medical to Promote and Distribute Abbotts FreeStyle Navigator Continuous Glucose Monitoring System
3. Abbott to Present at Cowen and Company Health Care Conference
4. Abbott to Present at Lehman Brothers Healthcare Conference
5. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
6. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
7. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
8. Abbott to Present at JP Morgan Healthcare Conference
9. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
10. Abbott Declares 336th Consecutive Quarterly Dividend
11. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Calif. , July 1, 2015   ... on the development of groundbreaking drugs to treat ... announced today that Robert G. Miller , ... at Sutter Health,s California Pacific Medical Center in San ... ALS Association for $1.5 million to help fund ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Apex Therapeutics ... BIO International Convention in Philadelphia, PA. , The presentation took place on ... outlined the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:6/30/2015)... - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that ... approved the resolutions relating to: (i) a private ... at a price of $2.67 per unit (the ... one common share and 0.075358 common share purchase ... and (ii) the amendment to Resverlogix,s articles to ...
(Date:6/30/2015)... ... 30, 2015 , ... uBiome and OpenBiome Partner for Microbiome ... fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, uBiome and OpenBiome ... microbiota transplantation (FMT) as a treatment for Clostridium difficile infections (C. diff). , ...
Breaking Biology Technology:Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... 24 United Therapeutics Corporation (Nasdaq: UTHR ... first quarter financial results before market open on Friday, ... on Friday, May 1, 2009, at 9:00 a.m. Eastern ... with international callers dialing 719-325-4795. A rebroadcast of ...
... plays a key role in determining risk for colorectal ... the United States. Several common genetic markers have ... finding the biological events that lead to cancer can ... online in Genome Research (www.genome.org), scientists have ...
... ULURU Inc. (NYSE Amex: ULU ) ... wounds using Altrazeal(TM) along with pre-clinical and physical data on ... Society for Advance Wound Care Conference ("SAWC") being held in ... data will be presented on posters on display during the ...
Cached Biology Technology:Beyond associations: Colorectal cancer culprit found 2ULURU to Present Clinical Evidence and Advanced Research on Altrazeal at the Society for Advance Wound Care Conference for 2009 2
(Date:6/23/2015)... Fla. , June 23, 2015 /PRNewswire/ ... management and authentication solutions, today announced enhanced functionality ... multi-factor authentication solution.  The enhancements build on ... of the DigitalPersona Altus platform and provide ... compatibility. In today,s environment of ...
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces that its ... segment on "Money on the Mark", scheduled to air on ... June 20 th . The broadcast ... from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino ...
(Date:6/17/2015)... Germany , June 17, 2015 ... Standard: QIA) today launched new Investigator ® STR assay ... the United States . The new genetic ... key genomic markers (short tandem repeats or STRs) for DNA ... evaluate the quality of DNA in each sample, a novel ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... (Cincinnati, OH) In a study published today in the ... an international team of researchers based in the U.S. and ... lethal, breath holding episodes associated with the neurological disease Rett ... that affects around 1 in 10,000 young girls. On October ...
... Institute in Boston have identified a new type of cell ... animal,s own cells from immune system attack. This ... drive lupus and other autoimmune diseases in which the immune ... The discovery, published in the September 16 issue of ...
... October 4, 2010 Onconova Therapeutics, Inc. announced ... regarding a Special Protocol Assessment (SPA) for the design ... 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), ... the bone marrow. The SPA provides FDA evaluation and ...
Cached Biology News:Research breakthrough hailed on the anniversary of gene discovery 2Discovery of a cell that suppresses the immune system 2Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS 2